This is a game changer for veterinarians and their ability to treat their patients with PRP”, said Mike Eldred, PetVivo Board ...
Molson Coors will assume exclusive commercialization rights to the company's Fever-Tree lineup of tonics, ginger beers and ...
Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...
Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company developing novel ...
Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated ...
Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused ...
Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ETCompany ParticipantsJoe Di Salvo – Vice President-Treasurer ...
Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only-mode. At the end of the prepared ...
Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...
NEW HAVEN, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company ...
Investing News Network on MSN4d
What is In-Licensing?When it comes to investing in pharmaceutical companies, looking at pipelines and research and development prospects is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback